Aya G. Halawi

Engineered NKG2C+ CD8+ TKLR cells exhibit effective antitumor control in mice while mitigating cytokine release syndrome.

Engineered T and NK cell therapies have widely been used to treat hematologic malignancies and solid tumors, with promising clinical results. Current chimeric antigen receptor (CAR) T cell therapeutics are, however, associated with treatment-related adverse events such as cytokine release syndrome (CRS) and are prone t...